Edward van Wezel, BioGeneration Ventures managing partner

Bio­Gen­er­a­tion Ven­tures clos­es $167M fund to hatch Eu­ro­pean star­tups with back­ing from Eli Lil­ly, No­vo, BMS

Bio­Gen­er­a­tion Ven­tures, a Dutch ven­ture cap­i­tal firm ded­i­cat­ed to ear­ly-stage biotech star­tups, has closed its fifth fund at €150 mil­lion ($167 mil­lion).

While BGV, based in Naar­den, Nether­lands, is fo­cused on drug de­vel­op­ers out of Eu­rope, the fund at­tract­ed a num­ber of fi­nan­cial in­sti­tu­tions or life sci­ences com­pa­nies of US ori­gin, which make up 78% of the new in­vestor base. Its ex­ist­ing cor­po­rate in­vestors, Eli Lil­ly, No­vo Hold­ings and Bris­tol My­ers Squibb, al­so re­turned for Fund V.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA